Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul 15;4(3):177-185.
doi: 10.15326/jcopdf.4.3.2017.0136.

The 2017 Update to the COPD Foundation COPD Pocket Consultant Guide

Barbara Bp Yawn  1 , Byron Thomashaw  2 , David M Mannino  3 , MeiLan K Han  4 , Ravi Kalhan  5 , Stephen Rennard  6 , Scott Cerrata  7 , James D Crapo  8 , Robert Wise  9
Affiliations
Review

The 2017 Update to the COPD Foundation COPD Pocket Consultant Guide

Barbara Bp Yawn et al. Chronic Obstr Pulm Dis. .

Abstract

The COPD Foundation Pocket Consultant Guide (PCG) was first released in 2007 as a practice tool for use at point of service for clinicians, especially primary care clinicians diagnosing and treating patients with chronic obstructive pulmonary disease (COPD). Over the years, the PCG has been supplemented with a mobile app that presents the tool in an online smart phone accessible version that also allows the clinician to enter patient specific data for guidance to next steps of diagnosis or management. In November 2016, a new update of the PCG was released that incorporates a flow diagram for stepped care that includes the newest recommendation for diagnosis, assessment and treatment; including the broad use of dual bronchodilator therapy and consideration of asthma COPD overlap syndrome (ACOS). The current controversy regarding when to add inhaled corticosteroids (ICSs) is addressed to support clinical decision making. The PCG comes in 2 versions, one with generic names for COPD drugs available in the United States and one with trade names for those drugs. The update continues to recommend spirometry for those at highest risk, also emphasizing the need to assess symptoms, exacerbation risks and comorbidity before selecting appropriate non-pharmacological as well as pharmacological therapy. The tool is designed to facilitate COPD management in daily practice.

Keywords: GOLD; care recommendations; chronic obstructive pulmonary disease; copd; guidelines; point of care; primary care.

PubMed Disclaimer

Conflict of interest statement

Barbara P. Yawn reports receiving COPD-related personal fees from Boehringer-Ingelheim, GlaxoSmithKline, AstraZeneca and Novartis and COPD-related research grant support from Boehringer-Ingelheim outside the submitted work. Scott Cerreta reports he has nothing to declare. MeiLan Han reports receiving personal fees from Sunovion, Boehringer-Ingelheim, GlaxoSmithKline, AstraZeneca and Novartis and receiving research grant support from Novartis and Sunovion outside the submitted work. David Mannino reports grants and personal fees from GlaxoSmithKline, personal fees from AstraZeneca, grants and personal fees from Novartis, personal fees from Amgen, grants and personal fees from Boehringer Ingelheim, personal fees from Merck, personal fees from Forest, personal fees from Up to Date, other from COPD Foundation, personal fees from Schlesinger Law Firm, non-financial support from Sunovion, outside the submitted work. Byron Thomashow reports receiving personal fees from Boehringer-Ingelheim, GlaxoSmithKline, AstraZeneca, and Novartis outside the submitted work. Robert Wise reports receiving personal fees from AstraZeneca, Boehringer-Ingelheim, Contrafect, GlaxoSmithKline, Merck, Novartis, Pulmonx, Roche-Genentech, Spiration, Sunovion, Teva and research grant support from AstraZeneca, Boehringer-Ingelheim, and GlaxoSmithKline outside the submitted work. Stephen Rennard is employed by AstraZeneca, Cambridge, United Kingdom. He reports receiving personal fees from Baxter, AstraZeneca, Dailchi Sankyo, Forest, Penn Technology, Novartis, Pulmirix, and Takeda as well as research grant support from Pfizer, GlaxoSmithKline, Boehringer Ingelheim, Nycomed, Astra-Zeneca, Centocor, and Almirall outside the submitted work. Ravi Kahlan reports personal fees from Forest Laboratories, Boehringer Ingelheim, Merck, Smith Medical, AstraZeneca, CVS Caremark, and Aptus Health, as well as research grant support from Boehringer Ingelheim, GlaxoSmithKline, PneumRx (BTG), Spiration, all outside the submitted work

References

    1. Kochanek KD,Murphy SL,Xu J,Tejada-Vera B. Deaths: Final Data for 2014. Nat Vital Stat Rep. 2016;65(4):1-121. - PubMed
    1. Ford ES,Croft JB,Mannino DM,Wheaton AG,Zhang X,Giles WH. COPD surveillance--United States, 1999-2011. Chest. 2013;144(1):284-305. doi: https://doi.org/10.1378/chest.13-0809 - PMC - PubMed
    1. Yawn B,Mannino D,Littlejohn T,et al. Prevalence of COPD among symptomatic patients in a primary care setting. Curr Med Res Opin. 2009;25(11):2671-2677. doi: https://doi.org/10.1185/03007990903241350 - PubMed
    1. Price D,Crockett A,Arne M,et al. Spirometry in primary care case-identification, diagnosis and management of COPD. Prim Care Respir J. 2009;18(3):216-223. doi: https://doi.org/10.4104/pcrj.2009.00055 - PMC - PubMed
    1. Mapel DW,Dalal AA,Blanchette CM,Petersen H,Ferguson GT. Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims. Int J Chron Obstruct Pulmon Dis. 2011;6:573-581. - PMC - PubMed